ArticleJournal of pharmaceutical policy and practice2016

The choice between a ritonavir-boosted protease inhibitor- and a non-nucleoside reverse transcriptase inhibitor-based regimen for initiation of antiretroviral treatment - results from an observational study in Germany.

Jörg Mahlich et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.